These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 38388753)

  • 1. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Cardoso P; Young KG; Nair ATN; Hopkins R; McGovern AP; Haider E; Karunaratne P; Donnelly L; Mateen BA; Sattar N; Holman RR; Bowden J; Hattersley AT; Pearson ER; Jones AG; Shields BM; McKinley TJ; Dennis JM;
    Diabetologia; 2024 May; 67(5):822-836. PubMed ID: 38388753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
    Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
    Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.
    Albulushi A; Tanoh DB; Almustafa A; Al Matrooshi N; Zolty R; Lowes B
    Cardiovasc Diabetol; 2024 Aug; 23(1):324. PubMed ID: 39217337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
    Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
    Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
    Dennis JM; Young KG; McGovern AP; Mateen BA; Vollmer SJ; Simpson MD; Henley WE; Holman RR; Sattar N; Pearson ER; Hattersley AT; Jones AG; Shields BM;
    Lancet Digit Health; 2022 Dec; 4(12):e873-e883. PubMed ID: 36427949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
    Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
    Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
    Blood AJ; Chang LS; Hassan S; Chasse J; Stern G; Gabovitch D; Zelle D; Colling C; Aronson SJ; Figueroa C; Collins E; Ruggiero R; Zacherle E; Noone J; Robar C; Plutzky J; Gaziano TA; Cannon CP; Wexler DJ; Scirica BM
    Circulation; 2024 Jun; 149(23):1802-1811. PubMed ID: 38583146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: A retrospective cohort study.
    Scoccimarro D; Cipani G; Dicembrini I; Mannucci E
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3727. PubMed ID: 37776322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
    Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
    Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
    Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
    Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine.
    Venkatasubramaniam A; Mateen BA; Shields BM; Hattersley AT; Jones AG; Vollmer SJ; Dennis JM
    BMC Med Inform Decis Mak; 2023 Jun; 23(1):110. PubMed ID: 37328784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.
    Al-Ozairi E; Irshad M; Taghadom E; Sojan L; Al Kandari J; Alroudhan D; le Roux CW
    Obesity (Silver Spring); 2023 Mar; 31(3):716-723. PubMed ID: 36811241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study.
    D'Onofrio L; Mignogna C; Carlone A; Bellizzi E; Di Guida M; Moretti C; Zampetti S; Leto G; Maddaloni E; Buzzetti R
    Diabetes Res Clin Pract; 2021 Mar; 173():108681. PubMed ID: 33516784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
    Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
    JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.
    Champion M; Wills Avila G; Garcia AE; Álvarez Delgado FM; Valdez CA
    J Prim Care Community Health; 2024; 15():21501319241231398. PubMed ID: 38353180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
    Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
    Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.